Eyepoint Pharmaceuticals, Inc. $EYPT Stock Holdings Increased by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC has increased its stake in Eyepoint Pharmaceuticals by 142.7%, owning a total of 625,140 shares valued at approximately $3.39 million following the purchase of 367,525 additional shares.
• Institutional investors now control 99.41% of Eyepoint Pharmaceuticals' stock, reflecting significant interest in the company from large financial entities.
• Eyepoint Pharmaceuticals reported a loss of ($0.85) EPS in its latest earnings announcement, falling short of analyst expectations, with total revenues of $5.33 million against a forecast of $6.82 million.

Hsbc Holdings PLC raised its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 142.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 625,140 shares of the company's stock after acquiring an additional 367,525 shares during the quarter. Hsbc Holdings PLC owned 0.91% of Eyepoint Pharmaceuticals worth $3,387,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. California State Teachers Retirement System grew its position in Eyepoint Pharmaceuticals by 3.8% in the fourth quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock valued at $362,000 after acquiring an additional 1,797 shares in the last quarter. Arizona State Retirement System grew its position in Eyepoint Pharmaceuticals by 12.7% in the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after acquiring an additional 1,877 shares in the last quarter. Legal & General Group Plc grew its position in Eyepoint Pharmaceuticals by 4.4% in the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock valued at $345,000 after acquiring an additional 1,932 shares in the last quarter. Invesco Ltd. raised its position in shares of Eyepoint Pharmaceuticals by 16.1% in the 4th quarter. Invesco Ltd. now owns 15,657 shares of the company's stock valued at $117,000 after purchasing an additional 2,177 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Eyepoint Pharmaceuticals by 5.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 71,238 shares of the company's stock valued at $531,000 after purchasing an additional 3,657 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Stock Down 0.3%

Shares of Eyepoint Pharmaceuticals stock traded down $0.03 during trading on Monday, hitting $11.57. The stock had a trading volume of 491,715 shares, compared to its average volume of 702,647. The stock has a 50 day simple moving average of $10.52 and a 200 day simple moving average of $7.91. The company has a market capitalization of $797.52 million, a PE ratio of -4.32 and a beta of 1.93. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.98.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The firm had revenue of $5.33 million during the quarter, compared to analysts' expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EYPT. Chardan Capital reaffirmed a "buy" rating and issued a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Royal Bank Of Canada assumed coverage on Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target on the stock. HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Finally, Mizuho reduced their price objective on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $26.86.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.